Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm
优化 SARS-CoV-2 复制和相关细胞因子风暴的小分子抑制剂
基本信息
- 批准号:10470714
- 负责人:
- 金额:$ 77.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAddressAnimal ModelAntiviral AgentsAntiviral resistanceBackBiological AvailabilityBuffersCOVID-19CYP3A4 geneCaco-2 CellsCellsDevelopmentDiseaseDoseDrug KineticsEnterovirusEnterovirus 71FutureGoalsGolgi ApparatusHourHumanIL8 geneIn VitroInterferonsInterleukin-6LeadLipidsMaximum Tolerated DoseMediatingMetabolicMetabolismModelingModificationMusOralOrganellesPeripheral Blood Mononuclear CellPermeabilityPharmaceutical ChemistryPhosphatidylinositolsPhosphotransferasesProductionProtein IsoformsResistanceResistance developmentRitonavirRoleSARS coronavirusSARS-CoV-2 infectionSARS-CoV-2 inhibitorSerumSevere Acute Respiratory SyndromeSiteSmall Interfering RNAStructure-Activity RelationshipTestingTherapeutic IndexTissuesToxic effectViralVirulentanaloganimal safetycytokinecytokine release syndromedrug developmentexperimental studyimprovedin vivoinhibitorknock-downlead optimizationmouse modelmultidisciplinarynanomolarnovelpre-clinicalremdesivirsafety studysevere COVID-19small molecule inhibitorstandard of caresynergismvirology
项目摘要
Our goal is to develop towards an IND a novel class of small molecule inhibitors of phosphoinositide (PI) 4
kinase IIIb (PI4KIIIb) with potent dual activity against both SARS-CoV-2 and the excess cytokine release
associated with COVID-19 disease. Entry of SARS-CoV has been shown to depend on PI4KIIIb, and strong
inhibition of entry was achieved following knockdown of PI4KIIIb via siRNA, and SARS-CoV-2 is believed to
enter cells via a similar mechanism. This likely reflects a requirement for enrichment of phosphorylated
isoforms of PI, such as PI-4, in the lipid organelle required for viral fusion upon entry. We have developed
potent and specific small molecule inhibitors of PI4KIIIb, and optimized them for high oral bioavailability. Our
lead inhibitor, STF-1019 has nanomolar efficacy against enteroviruses (EV) which are also dependent on
PI4KIIIb, and is the only molecule to have demonstrated in vivo efficacy in the animal model of EV-71, and
without toxicity. We have now shown that STF-1019’s EC50 against SARS-CoV-2 is 210 nM, with a CC50 of
>100 microM, reflecting a therapeutic index (TI) of ~500. Finally, likely due to PI4KIIIb’s role in Golgi-mediated
secretion, we have also recently shown that STF-1019 can potently inhibit the LPS-induced secretion of IL-6
from human PBMC. STF-1019’s metabolic stability, however, is suboptimal, requiring co-administration with an
inhibitor (i.e. ritonavir) of its metabolism by CYP3A4 for optimal sustained tissue exposure. We hypothesize
that: 1) STF-1019’s SAR and major metabolites indicates that our lead PI4KIIIb inhibitor can be further
optimized to increase its activity and metabolic stability to achieve an optimal exposure profile; 2) modifications
that further increase PI4KIIIb inhibition can provide a buffer for modifications that may increase metabolic
stability at the expense of efficacy; 3) the optimized inhibitor will inhibit SARS-CoV-2 in vitro, and in vivo; 4) the
optimized inhibitor will have a high barrier to the development of resistance; 5) because of its orthogonal
mechanism of action, our PI4KIIIb inhibitor can be used in combination with other agents to maximize efficacy;
6) STF-1019’s inhibition of IL-6 reflects an ability to modulate the release of other cytokines, and this non-
antiviral activity can be of great additional benefit in addressing the cytokine storm associated with severe
COVID-19 infection; 7) determination of key pharmacokinetic, in vitro ADME-Tox parameters and initial
preclinical in vivo toxicity assessment of our optimized lead can advance its translational development, and
form the basis of a future IND package. We propose the test these hypotheses by: 1) Identifying the STF-1019
analog (and back-up compound) with greatest in vivo trough:EC90 ratios; 2) determining the in vivo activity of
the optimized PI4KIIIb inhibitors against SARS-CoV-2 and their effect on cytokine production; 3) determining
the relative barrier to resistance, and potential for synergy with other agents; and 4) nominating a PI4KIIIb
inhibitor IND candidate by subjecting the optimized lead to initial in vitro ADME-tox and IND-enabling
preclinical animal safety studies.
我们的目标是开发一类新型磷酸肌醇 (PI) 4 小分子抑制剂
激酶 IIIb (PI4KIIIb) 具有针对 SARS-CoV-2 和过量细胞因子释放的有效双重活性
与 COVID-19 疾病相关。 SARS-CoV 的进入已被证明依赖于 PI4KIIIb,并且强烈
通过 siRNA 敲低 PI4KIIIb 后实现了进入抑制,并且 SARS-CoV-2 被认为
通过类似的机制进入细胞。这可能反映了对磷酸化物质富集的要求
PI 亚型,例如 PI-4,存在于病毒进入时融合所需的脂质细胞器中。我们开发了
PI4KIIIb 的有效且特异性小分子抑制剂,并对其进行了优化以获得高口服生物利用度。我们的
主要抑制剂 STF-1019 对肠道病毒 (EV) 具有纳摩尔级功效,这也依赖于
PI4KIIIb,是唯一在 EV-71 动物模型中证明体内功效的分子,并且
无毒性。我们现已证明 STF-1019 针对 SARS-CoV-2 的 EC50 为 210 nM,CC50 为
>100 microM,反映治疗指数 (TI) 约为 500。最后,可能是由于 PI4KIIIb 在高尔基体介导中的作用
分泌,我们最近还表明 STF-1019 可以有效抑制 LPS 诱导的 IL-6 分泌
来自人类 PBMC。然而,STF-1019 的代谢稳定性并不理想,需要与
CYP3A4 代谢的抑制剂(即利托那韦),以实现最佳的持续组织暴露。我们假设
1) STF-1019 的 SAR 和主要代谢物表明我们的主要 PI4KIIIb 抑制剂可以进一步
优化以提高其活性和代谢稳定性,以实现最佳暴露曲线; 2)修改
进一步增加 PI4KIIIb 抑制可以为可能增加代谢的修饰提供缓冲
以牺牲功效为代价的稳定性; 3)优化的抑制剂将在体外和体内抑制SARS-CoV-2; 4)
优化的抑制剂将对耐药性的产生具有较高的屏障; 5)由于其正交
作用机制,我们的 PI4KIIIb 抑制剂可以与其他药物联合使用,以最大限度地提高疗效;
6) STF-1019 对 IL-6 的抑制反映了调节其他细胞因子释放的能力,并且这种非-
抗病毒活性对于解决与严重疾病相关的细胞因子风暴具有巨大的额外益处
2019冠状病毒病感染; 7) 关键药代动力学、体外 ADME-Tox 参数和初始值的测定
我们优化的先导化合物的临床前体内毒性评估可以促进其转化开发,并且
形成未来 IND 计划的基础。我们建议通过以下方式测试这些假设:1) 识别 STF-1019
具有最大体内谷值的类似物(和备用化合物):EC90 比率; 2) 测定体内活性
针对 SARS-CoV-2 的优化 PI4KIIIb 抑制剂及其对细胞因子产生的影响; 3)确定
耐药性的相对屏障以及与其他药物协同作用的潜力; 4) 提名 PI4KIIIb
抑制剂 IND 候选药物,通过对优化的先导化合物进行初始体外 ADME-tox 和 IND 启用
临床前动物安全性研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY S GLENN其他文献
JEFFREY S GLENN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY S GLENN', 18)}}的其他基金
Oral small molecule inhibitors of NSP4-mediated membrane-associated RNA replication of SARS-CoV-2 and other RNA viruses
NSP4 介导的 SARS-CoV-2 和其他 RNA 病毒膜相关 RNA 复制的口服小分子抑制剂
- 批准号:
10514275 - 财政年份:2022
- 资助金额:
$ 77.21万 - 项目类别:
Development of outpatient antiviral cocktails against SARS-CoV-2 and other potential pandemic RNA viruses.
开发针对 SARS-CoV-2 和其他潜在大流行性 RNA 病毒的门诊抗病毒鸡尾酒。
- 批准号:
10514264 - 财政年份:2022
- 资助金额:
$ 77.21万 - 项目类别:
Programmable antivirals: Targeting viral RNA secondary structures with LNAs and small molecules
可编程抗病毒药物:利用 LNA 和小分子靶向病毒 RNA 二级结构
- 批准号:
10514269 - 财政年份:2022
- 资助金额:
$ 77.21万 - 项目类别:
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm
优化 SARS-CoV-2 复制和相关细胞因子风暴的小分子抑制剂
- 批准号:
10681264 - 财政年份:2021
- 资助金额:
$ 77.21万 - 项目类别:
Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm
优化 SARS-CoV-2 复制和相关细胞因子风暴的小分子抑制剂
- 批准号:
10187861 - 财政年份:2021
- 资助金额:
$ 77.21万 - 项目类别:
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
将广谱抗甲型流感病毒 RNA 包装抑制剂推进 IND
- 批准号:
10165884 - 财政年份:2020
- 资助金额:
$ 77.21万 - 项目类别:
Rapid development of SARS-CoV-2 specific therapeutics that leverage virus specific RNA elements
利用病毒特异性 RNA 元件快速开发 SARS-CoV-2 特异性疗法
- 批准号:
10115505 - 财政年份:2020
- 资助金额:
$ 77.21万 - 项目类别:
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
将广谱抗甲型流感病毒 RNA 包装抑制剂推进 IND
- 批准号:
9750617 - 财政年份:2017
- 资助金额:
$ 77.21万 - 项目类别:
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
将广谱抗甲型流感病毒 RNA 包装抑制剂推进 IND
- 批准号:
9973144 - 财政年份:2017
- 资助金额:
$ 77.21万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 77.21万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 77.21万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 77.21万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 77.21万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 77.21万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 77.21万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 77.21万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 77.21万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 77.21万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 77.21万 - 项目类别:
Research Grant














{{item.name}}会员




